04 May Invenra Partners with Exelixis to Develop New Antibody Cancer Drugs
Invenra, a URP tenant / biotech startup that develops therapeutic antibodies for pharma companies, is joining forces with a Bay Area company to discover and develop new treatments for cancer.
Under the agreement, Exelixis will pay Invenra $2 million upfront, plus an additional $2 million at the outset of each new discovery project, the company said. Exelixis will receive an exclusive global license to one preclinical asset, Invenra said.